Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganlibao
- Development stage
- Unknown
- Lead developer
- Beijing Huaxia Yisheng Innovation Technology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ganlibao is a therapeutic hepatitis B vaccine developed by Beijing Huaxia Yisheng Innovation Technology for the treatment of chronic hepatitis B (CHB). It is a recombinant protein subunit vaccine, typically produced in Chinese Hamster Ovary (CHO) cells, containing hepatitis B virus (HBV) antigens such as the surface antigen (HBsAg) and the core antigen (HBcAg). Unlike prophylactic vaccines, Ganlibao is designed to break the immune tolerance characteristic of chronic HBV infection by stimulating a robust, antigen-specific T-cell response. The vaccine is administered via intramuscular injection and has been evaluated in Phase II and Phase III clinical trials in China, often in combination with antiviral therapies like nucleoside analogs to achieve a functional cure, defined by HBsAg seroconversion.
- Brand names
- Ganlibao
- Other names
- Therapeutic Hepatitis B VaccineRecombinant Hepatitis B Vaccine (CHO Cell)
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Ganlibao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganlibao.